trending Market Intelligence /marketintelligence/en/news-insights/trending/nAky-fOhMhnC3Y-Se8QOvA2 content esgSubNav
In This List

MabVax stockholders approve reverse stock split

Blog

Insight Weekly: Ukraine war impact on mining; US bank growth slowdown; cloud computing headwinds

Blog

Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall

Blog

Global M&A By the Numbers: Q1 2022

Blog

Insight Weekly: Challenges for European banks; Japan's IPO slowdown; carmakers' supply woes


MabVax stockholders approve reverse stock split

MabVax Therapeutics Holdings Inc. stockholders approved the implementation of a reverse stock split of its issued and outstanding common shares at a special meeting held Oct. 6.

The company may initiate the stock split at any time prior to Sept. 28, 2018. The exact split ratio is still pending on the board's direction but will not be less than 1-for-2 and not more than 1-for-20.

The reverse stock split will allow MabVax to regain compliance with Nasdaq Capital Market's $1 minimum bid price listing requirement. The company has 180 calendar days, or until March 5, 2018 to regain compliance with the listing standard.